Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 With Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants

IMPAACT 2008

The purpose of this study was to evaluate the safety and antiviral activity to promote clearance of HIV-1 infected cells of VRC01 in infants with HIV beginning combination antiretroviral therapy (cART).

2018-08-06

2020-06-16

2021-02-11

Completed

Early phase I

61

Infant Inclusion Criteria: * Weigh at least 2500 grams * Confirmed HIV-1 infection * The following laboratory values at screening: * Cluster of differentiation 4 (CD4) lymphocyte percentage greater than 15 * Severity grade 1 or lower hemoglobin, platelet count, and absolute neutrophil count * Severity grade 1 or lower alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase * First dose of initial combination antiretroviral therapy (cART) regimen taken on the day of randomization or within 14 days prior to the day of randomization * Expected to be available for 48 weeks of follow-up at study entry * Parent or legal guardian willing and able to provide written informed consent for infant participation in the study * Parent or legal guardian willing and able to complete reactogenicity memory aids for study purposes, based on parent/guardian report. Infant Exclusion Criteria: * Infant or infant's mother received exclusionary active or passive HIV-specific immunotherapy * Initiated a combination of three or more antiretrovirals, all at or above recommended treatment doses, within 48 hours of birth * Received within 30 days prior to study entry, or was identified as requiring, any of the following: * Chronic (more than 14 days) systemic steroid treatment * Immunoglobulin treatment * Immunomodulators (interleukins, interferons, cyclosporin) * Cytotoxic chemotherapy * Treatment for active tuberculosis (TB) disease * Any investigational agent * Note: Treatment for latent TB infection was permitted * Any documented or suspected clinically significant medical illness, clinically significant congenital anomaly, or immediately life-threatening condition that, in the opinion of the site investigator or designee, would interfere with the infant's ability to comply with study requirements * Any other condition that, in the opinion of the site investigator or designee, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives Maternal Inclusion Criteria (maternal study participation was not required for infant study participation): The mothers of enrolled infants were asked to consent to blood collection and storage for this study. The following criteria must have been met in order for mothers to undergo blood collection for this purpose: * Mother was willing and able to provide independent written informed consent for blood collection and storage for virology and immunology investigations * Mother had no documented or suspected condition that, in the opinion of the site investigator or designee, would make blood collection unsafe

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 61, 'type': 'ACTUAL'}}

2023-05-24